Overview Dividends

(SIGA) SIGA Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8269171067

Antiviral, Smallpox, TPOXX, Health Security

Pharmaceuticals
Market Cap in USD: 418m

IPO / Inception: 1997-09-09
Return 12m vs S&P 500: -17.2%

EPS (Earnings per Share)

EPS CAGR: -78.27%
EPS Trend: -10.7%

Last SUE: -0.51
Qual. Beats: 0

Revenue

Rev. CAGR: -63.55%
Rev. Trend: -16.4%

Last SUE: 0.44
Qual. Beats: 0

Dividends

Dividend Yield	9.93%
Yield on Cost 5y	11.83%
Yield CAGR 5y	15.47%
Payout Consistency	98.8%
Payout Ratio	57.9%

Risk via 10d forecast
Volatility	61.0%
Value at Risk 5%th	89.3%
Relative Tail Risk	-11.07%

Reward TTM
Sharpe Ratio	0.00
Alpha	-8.74
CAGR/Max DD	-0.09

Character TTM
Hurst Exponent	0.446
Beta	0.661
Beta Downside	0.446

Drawdowns 3y
Max DD	56.39%
Mean DD	33.58%
Median DD	36.66%

Description: SIGA SIGA Technologies October 24, 2025

SIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage biopharma focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.

Key metrics as of the latest filing (Q2 2024): cash and short-term investments of roughly $140 million, a net loss of $32 million for the trailing twelve months, and a market-cap near $350 million. The company’s revenue is driven almost entirely by government contracts for TPOXX, which together with the broader biodefense budget (projected to grow at ~4% CAGR) constitute its primary economic driver.

Sector trends that affect SIGA include heightened federal spending on pandemic preparedness and the expanding “health-security” niche, which has attracted increased R&D incentives and potential partnership opportunities with defense contractors.

For a deeper, data-rich analysis of SIGA’s valuation and peer landscape, you may find ValueRay’s research tools helpful.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (74.5m TTM) > 0 and > 6% of Revenue (6% = 10.3m TTM)

FCFTA 0.50 (>2.0%) and ΔFCFTA 13.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 117.8% (prev 91.17%; Δ 26.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.50 (>3.0%) and CFO 116.6m > Net Income 74.5m (YES >=105%, WARN >=100%)

Net Debt (-171.0m) to EBITDA (94.3m) ratio: -1.81 <= 3.0 (WARN <= 3.5)

Current Ratio 9.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (71.6m) change vs 12m ago -0.23% (target <= -2.0% for YES)

Gross Margin 76.29% (prev 78.34%; Δ -2.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 80.69% (prev 88.93%; Δ -8.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -29.47 (EBITDA TTM 94.3m / Interest Expense TTM -3.18m) >= 6 (WARN >= 3)

Altman Z'' 6.76

(A) 0.88 = (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m

(B) -0.16 = Retained Earnings (Balance) -37.6m / Total Assets 231.6m

(D) -1.34 = Book Value of Equity -37.6m / Total Liabilities 28.1m

Total Rating: 6.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 80.23

1. Piotroski 4.50pt

2. FCF Yield 47.06%

3. FCF Margin 67.52%

4. Debt/Equity 0.00

5. Debt/Ebitda -1.81

6. ROIC - WACC (= 25.39)%

7. RoE 35.26%

8. Rev. Trend -16.38%

9. EPS Trend -10.74%

What is the price of SIGA shares?

As of November 28, 2025, the stock is trading at USD 6.04 with a total of 229,444 shares traded.
Over the past week, the price has changed by +2.20%, over one month by -28.35%, over three months by -28.86% and over the past year by -5.12%.

Is SIGA a buy, sell or hold?

SIGA Technologies has no consensus analysts rating.

What are the forecasts/targets for the SIGA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	17.5	190.2%
Analysts Target Price	17.5	190.2%
ValueRay Target Price	6	-0.3%

SIGA Fundamental Data Overview November 25, 2025

Market Cap USD = 418.2m (418.2m USD * 1.0 USD.USD)
P/E Trailing = 5.6699
P/E Forward = 3.8745
P/S = 2.4279
P/B = 2.0588
Beta = 0.972
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 247.2m USD (418.2m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
FCF Yield = 47.06% (FCF TTM 116.3m / Enterprise Value 247.2m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.07 (Enterprise Value 247.2m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 23.82% (-1.99m / -8.36m)
NOPAT = 71.4m (EBIT 93.7m * (1 - 23.82%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.15% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 33.82% (NOPAT 71.4m / Invested Capital 211.2m)
WACC = 8.43% (E(418.2m)/V(419.1m) * Re(8.45%) + (debt cost/tax rate unavailable))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈98.4m ; Y1≈121.4m ; Y5≈207.0m
Fair Price DCF = 45.45 (DCF Value 3.25b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -10.74 | EPS CAGR: -78.27% | SUE: -0.51 | # QB: 0
Revenue Correlation: -16.38 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0

Additional Sources for SIGA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle